Fatal bleeding , as evaluated in the intention-to-treat analysis, occurred in 34 individuals in the apixaban group and 55 sufferers in the warfarin group. Subgroups The reduction in the primary outcome with apixaban was constant across all major subgroups , and statistical tests for interaction were not significant for every one of the 21 predefined subgroups. With regards to the end result of major bleeding, the just baseline characteristics that the conversation was significant were diabetes position and renal function, with a greater decrease in bleeding among sufferers who didn’t have diabetes and among individuals with moderate or severe renal impairment .Our RPE technology is definitely safe, provides and scalable tremendous prospect of treating many of the 200-in addition retinal diseases. This patent should help us in attaining our objective of becoming one of the dominant players in this possibly very large marketplace. Related StoriesCharles Bonnet syndrome: an interview with Dr. Dominic ffytcheSome antibiotics could make MRSA even more harmfulGood news for sufferers suffering from dry age-related macular degenerationThe issuance of this patent may be the latest in several encouraging advancements for ACT’s RPE system: At the end of last year the business filed an Investigational New Medication Software with the FDA.